Discontinued — last reported Q4 '23
Net sales — Net Sales
Viatris Net sales — Net Sales remained flat by 0.0% to $3.85B in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 5.1%, from $4.05B to $3.85B. Over 2 years (FY 2021 to FY 2023), Net sales — Net Sales shows a downward trend with a -7.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests growing market demand or successful pricing strategies, while a decrease may indicate market share loss, pricing pressure, or product lifecycle maturity.
Detailed definition
This metric represents the total revenue generated from the sale of goods and services within a specific business segmen...
Peer comparison
Comparable to 'Segment Revenue' or 'Net Sales by Operating Segment' reported by other global pharmaceutical and generic drug manufacturers.
vtrs_segment_net_sales_net_salesHistorical Data
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $17.81B | $16.22B | $15.39B |
| YoY Change | — | -9.0% | -5.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's net sales — net sales?
- Viatris (VTRS) reported net sales — net sales of $3.85B in Q4 2023.
- How has Viatris's net sales — net sales changed year-over-year?
- Viatris's net sales — net sales decreased by 5.1% year-over-year, from $4.05B to $3.85B.
- What is the long-term trend for Viatris's net sales — net sales?
- Over 2 years (2021 to 2023), Viatris's net sales — net sales has grown at a -7.1% compound annual growth rate (CAGR), from $17.81B to $15.39B.
- What does net sales — net sales mean?
- The total revenue earned by a specific business segment after accounting for returns and discounts.